AvalehtBMY • NYSE
add
Bristol-Myers Squibb Co
Viimane sulgemishind
45,61 $
Tänane vahemik
45,43 $ - 46,51 $
Aasta vahemik
42,52 $ - 63,33 $
Turuväärtus
92,79 mld USD
Keskmine maht
18,65 mln
P/E suhe
15,37
Dividendimäär
5,45%
Põhibörs
NYSE
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Käive | 12,22 mld | 2,77% |
Põhitegevusega seonduv kulu | 5,05 mld | −26,13% |
Puhastulu | 2,20 mld | 81,75% |
Puhaskasumimarginaal | 18,01 | 76,92% |
Puhaskasum aktsia kohta | 1,63 | −9,44% |
EBITDA | 4,91 mld | 1,38% |
Tõhus maksumäär | 29,51% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 16,50 mld | 103,88% |
Kogu vara | 96,89 mld | 3,44% |
Kõik kohustused | 78,29 mld | 2,38% |
Kogu omakapital | 18,60 mld | — |
Emiteeritud aktsiate arv | 2,04 mld | — |
Hinna ja väärtuse suhe P/B | 5,01 | — |
Varade tasuvus | 10,07% | — |
Kapitali tasuvus | 13,97% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Puhastulu | 2,20 mld | 81,75% |
Põhitegevuse rahakäive | 6,31 mld | 12,88% |
Investeeringute raha | −1,70 mld | −677,17% |
Finantseerimise raha | −1,49 mld | 61,32% |
Raha ja raha ekvivalentide muutus | 3,12 mld | 95,05% |
Tasuta rahavoog | 4,26 mld | −23,81% |
Teave
Bristol-Myers Squibb Company is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are Apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.
BMS's primary research and development sites are located in Lawrence, New Jersey, Summit, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey; Redwood City, California; and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts; Braine-l'Alleud, Belgium; Tokyo, Japan; Hyderabad; Bangalore, India and Wirral, United Kingdom. Wikipedia
Tegevjuht
Asutatud
1887
Veebisait
Töötajate arv
34 100
